Abstract
The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser → Leu 217) and (Ala → Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in prostate cancer cases. To evaluate this hypothesis we genotyped 432 prostate cancer patients (including 262 patients diagnosed ≤ 55 years) and 469 UK, population based control individuals with no family history of cancer. We found no significant difference in the frequencies of Thr541-containing genotypes between cases and controls (OR=1.41, 95% CI 0.79-2.50). The association remained non-significant when the analysis was restricted to cases divided by age of onset into those diagnosed ≤ 55 years (OR=1.50, 95% CI 0.79-2.85) or to patients diagnosed > 55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak. © 2002 Cancer Research UK.
Author supplied keywords
Cite
CITATION STYLE
Meitz, J. C., Edwards, S. M., Easton, D. F., Murkin, A., Ardern-Jones, A., Jackson, R. A., … Eeles, R. A. (2002). HPC2/ELAC2 polymorphisms and prostate cancer risk: Analysis by age of onset of disease. British Journal of Cancer, 87(8), 905–908. https://doi.org/10.1038/sj.bjc.6600564
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.